Organogenesis Holdings Inc (ORGO)
NASDAQ:ORGO

Organogenesis Holdings (ORGO) Stock Price & Analysis

364 Followers

ORGO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.23 - $9.27
Previous Close$2.8
Volume622.69K
Average Volume (3M)672.61K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$107.25M
Total Debt (Recent Filing)$130.71M
Price to Earnings (P/E)6.1
Beta1.18
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)0.46
Shares Outstanding130,915,099
R-Squared0.14
Standard Deviation0.22
10 Day Avg. Volume615,943
30 Day Avg. Volume672,608
Price to Book (P/B)1.63
Price to Sales (P/S)1.03
Price to Cash Flow (P/CF)9.70
P/FCF Ratio-54.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.03
Number of Analyst Covering1


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ORGO FAQ

What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $2.23 and its highest was $9.27 in the past 12 months.
    What is Organogenesis Holdings’s market cap?
    Currently, no data Available
    When is Organogenesis Holdings’s upcoming earnings report date?
    Organogenesis Holdings’s upcoming earnings report date is Mar 14, 2023 which is in 38 days.
      How were Organogenesis Holdings’s earnings last quarter?
      Organogenesis Holdings released its earnings results on Nov 09, 2022. The company reported $0.037 earnings per share for the quarter, missing the consensus estimate of $0.059 by -$0.022.
        Is Organogenesis Holdings overvalued?
        According to Wall Street analysts Organogenesis Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Organogenesis Holdings pay dividends?
          Organogenesis Holdings does not currently pay dividends.
          What is Organogenesis Holdings’s EPS estimate?
          Organogenesis Holdings’s EPS estimate is $0.06.
            How many shares outstanding does Organogenesis Holdings have?
            Organogenesis Holdings has 130,915,100 shares outstanding.
              What happened to Organogenesis Holdings’s price movement after its last earnings report?
              Organogenesis Holdings reported an EPS of $0.037 in its last earnings report, missing expectations of $0.059. Following the earnings report the stock price went down -14.887%.
                Which hedge fund is a major shareholder of Organogenesis Holdings?
                Among the largest hedge funds holding Organogenesis Holdings’s share is Royce & Associates LLC. It holds Organogenesis Holdings’s shares valued at 54K.

                  ---

                  Organogenesis Holdings Stock Smart Score

                  The Organogenesis Holdings stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Organogenesis Holdings Inc

                  Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Kodiak Sciences
                  89bio
                  Precigen
                  Protagonist Therapeutics
                  MiMedx Group

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis